

How Can Shape Memory Plug Embolization Be Used To Improve Results After TEVAR For Degenerative Aneurysm And TBAD

Virendra I. Patel, MD MPH
Auchincloss Associate Professor of Surgery
Vascular Surgery and Endovascular Interventions

COLUMBIA UNIVERSITY College of Physicians & Surgeons DEPARTMENT OF SURGERY

NewYork-Presbyterian

ColumbiaDoctors Aortic Center

Disclosures

Speaker name:

Virendra I. Patel MD MPH

I have the following potential conflicts related to this presentation to report:

Speaker/Consultant

- COOK / Terumo / Altrivion / GE / Shape Memory Medical

Principal Investigator

- SMART EVAR trial

Off-label use**ColumbiaDoctors Aortic Center****aorticcenter@cumc.columbia.edu****NewYork-Presbyterian**

Sac Behavior following EVAR

From the Society for Clinical Vascular Surgery

Aneurysm sac failure to regress after endovascular aneurysm repair is associated with lower long-term survival

Thomas F. X. O'Donnell, MD; Smith E. Garry, MD, MPH;¹ Laura T. Bolano, MD;² Jeffrey J. Sircusce, MD;³ Marc L. Schermerhorn, MD;⁴ Salvatore T. Scali, MD;⁵ Andrew Schanzer, MD;⁶ Robert T. Lancaster, MD, MPH;⁷ and Virendra I. Patel, MD, MPH.⁸ Boston and Worcester, Mass; Gainesville, Fla; and New York, NY⁹

- Infrarenal AAA – VQI 2003 – 2017
- 14817 patients
- Pre-op and one year AAA diameter

ColumbiaDoctors Aortic Center

NewYork-Presbyterian

Results

- Sac behavior:**
 - 40% regressed
 - 35% remained stable
 - 25% expanded

ColumbiaDoctors Aortic Center

NewYork-Presbyterian

Long-Term Mortality – Impact of Sac Behavior

Freedom from all-cause mortality

IP < 0.01 for all comparisons, SE < 0.1.
n = 14,817 in VQI study
From Sing et al 2018

Stable sac:
HR 1.20
[1.03 – 1.39]
P = .02

Sac expansion:
HR 1.63
[1.28 – 2.07]
P < 0.001

ColumbiaDoctors Aortic Center

NewYork-Presbyterian

Long-Term Mortality Hazard

Adjusted Hazard Ratios for Mortality, by Sac Change

Sac Change Category	Adjusted Hazard Ratio (HR)
Regres < 10.1-15mm	~1.4
Regres 10.1-15mm	~1.4
Expans 0.1-1.5mm	~1.4
Expans 1.6-5.9mm	~1.8
Expans 6.0-14.9mm	~2.0
Expans >15mm	~2.5

ColumbiaDoctors Aortic Center

NewYork-Presbyterian

VQI / VISION TEVAR and Sac Behavior

Retrospective / Multi-center VQI VISION - 2014 to 2018

- Vascular Implant Surveillance & Interventional Outcomes Network (VISION)
- VQI + Medicare
- Inclusion
 - All TEVAR of the descending thoracic aorta
 - Repair for aortic aneurysm, dissection, PAU, IMH
 - Data on 1-year postoperative imaging
- Exclusion
 - Ruptured repair
 - Missing preoperative or 1-year follow-up aortic diameter measurements

ColumbiaDoctors Aortic Center NewYork-Presbyterian

Results

- TAA Sac behavior:
- 39% Aortic regression
- 38% remained stable
- 23% expanded

ColumbiaDoctors
Aortic Center



NewYork-
Presbyterian

Predictors of Failure to Regress

	Odds Ratio	95% CI	P-value
Aortic diameter (per cm)	0.6	0.6 – 0.7	<.001
Completion Endoleak			
None	Ref	--	--
Type I or III	2.5	1.2 – 5.2	.019
Type II	1.3	0.5 – 3.2	.618
1 year Endoleak			
None	Ref	--	--
Type I or III	3.3	1.5 – 7.3	.003
Type II	3.2	1.3 – 7.8	.011

ColumbiaDoctors Aortic Center NewYork-Presbyterian

Decreased Re-intervention w. Regression

Late Reintervention

	aHR (95% CI)	P-value
Regression	Ref	--
Exp/Stable	1.5 (1.1 - 2.1)	.033

ColumbiaDoctors Aortic Center NewYork-Presbyterian

Decreased Late Rupture w. Regression

Late Rupture

	aHR (95% CI)	P-value
Regression	Ref	--
Exp/Stable	4.6 (1.3 - 16)	.017

ColumbiaDoctors Aortic Center NewYork-Presbyterian

Survival not Associated with Sac Change

Mortality

	aHR (95% CI)	P-value
Regression	Ref	--
Exp/Stable	1.4 (0.7 - 2.6)	.33

ColumbiaDoctors Aortic Center NewYork-Presbyterian

Treatment of Sac during EVAR / TEVAR

Endograft excludes the sac

- Biologically active thrombus triggers acute and chronic inflammation
- Endoleak perfuses/presurizes sac

ColumbiaDoctors
Aortic Center

Pre-emptive IMA Embolization

Samura M, et al. Ann Surg 2020;271:238-244

RANDOMIZED CONTROLLED TRIAL

Endovascular Aneurysm Repair With Inferior Mesenteric Artery Embolization for Preventing Type II Endoleak
A Prospective Randomized Controlled Trial

Makoto Samura, MD, Noriyasu Morikage, MD, Ryo Otsuka, MD, Takahiro Mizoguchi, MD, Naoto Tsuchihashi, MD, Toshiaki Ueda, MD, Tomohiko Hidai, MD, Junji Yamamoto, MD

• Randomized 106 patients at high risk of T2EL
• IMA Embolization + EVAR (n=53) or standard EVAR (n=53)

ColumbiaDoctors
Aortic Center

NewYork-Presbyterian

Pre-emptive IMA Embolization

Samura M, et al. Ann Surg 2020;271:238-244

TABLE 5. Clinical Outcomes in the Per-protocol Analysis

Variables	Embolization (n = 46)	Nonembolization (n = 51)	P	ARR (95% CI)	NNT (95% CI)
Follow-up periods, mo	23.9 ± 10.9	23.2 ± 11.0	0.76		
Presence of T2EL	10 (21.7%)	24 (47.1%)	0.009	25.3% (6.4%-41.0%)	3.9 (2.4-15.6)
Source of T2EL (% in T2EL presence)					
LAs	11 (100%)	12 (50.0%)		3 (12.5%)	
IMA + LAs	0	6 (25.0%)			
Others (IMA, LAs + MSA, or ARA)	0	3 (12.5%)			
Aneurysmal diameter change, mm	-6.3 ± 7.5	-2.5 ± 3.7	0.021		
Aneurysmal growth ≥2 mm related to T2EL	1 (2.2%)	9 (17.6%)	0.017	15.5% (3.6%-18.9%)	6.5 (5.3-27.6)
Source of T2EL (% in related to T2EL)					
IMA + LAs	0	8 (88.9%)			
Others	1 (100%)	1 (22.2%)			
Secondary intervention	1 (2.2%)	1 (2.0%)	1.00		
Reoperation	0	0			

ARA indicates accessory renal artery; ARR, absolute risk reduction; CI, confidence interval; IMA, inferior mesenteric artery; LA, lumbar artery; MSA, medial sacral artery; NNT, number needed to treat; T2EL, type II endoleak.

ColumbiaDoctors
Aortic Center

NewYork-Presbyterian

Pre-emptive Aneurysm Sac Embolization

Piazza M, et al. J Vasc Surg 2016;63:32-8.

• Sac embolization significantly reduces the incidence of type II endoleaks
• At discharge, 8/26 vs. 33/44 ($p < .001$)
• At 12 months, 5/25 vs. 32/44 ($p < .001$)

• Failure of sac embolization:
• Higher endoluminal residual sac volume
• Lower concentration of coils implanted

ColumbiaDoctors
Aortic Center

NewYork-Presbyterian

Pre-emptive Thoracic Aneurysm Embo.

Jacky Ho, et al. Ann Thorac Surg 2016;102:489-91.

ColumbiaDoctors
Aortic Center

NewYork-Presbyterian

Pre-emptive Segmental Artery Embolization

From the Society for Vascular Surgery

Type II endoleak and aortic aneurysm sac shrinkage after preemptive embolization of aneurysm sac side branches

Daniela Branzan, MD,^a Antonia Geisler,^a Sabine Steiner, MD, PhD,^b Markus Doss, MD,^a Manuela Matschuck, MD,^b Dierk Scheinert, MD, PhD,^b and Andrej Schmidt, MD, PhD,^b Leipzig, Germany

139 Patients 2014 – 2019 side branch embolization
76% Branch vessel occlusion
5% T2L
87% sac shrinkage

ColumbiaDoctors
Aortic Center

Branzan, et al. J Vasc Surg 2021;73:1973-9.

NewYork-Presbyterian

Pre-emptive Segmental Artery Embolization

Minimally invasive staged segmental artery coil embolization (MIS²ACE) for spinal cord protection

Josephina Haunschmid¹, Tilo Köbel¹, Martin Misfeld^{1,3,4,5,6,7}, Christian D. Ertz¹

¹Department of Cardiac Surgery, University Heart Center, Rostock University Medical Center, Rostock, Germany; ²German Aortic Center, Department of Vascular Medicine, University Heart and Vascular Center, Hamburg, Germany; ³Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia; ⁴University Department for Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany; ⁵Sydney Medical School, University of Sydney, Sydney, NSW, Australia; ⁶Institute of Academic Surgery, RPAR, Sydney, Australia; ⁷The Baird Institute of Applied Heart and Lung Surgical Research, Sydney, Australia

Correspondence to: Christian D. Ertz, MD, PhD, Department of Cardiac Surgery, University Heart Center, Rostock University Medical Center, Schillingsallee 33, 18057 Rostock, Germany. Email: Christian.ertz@med.uni-rostock.de.

ColumbiaDoctors Aortic Center | NewYork-Presbyterian

Haunschmid, et al. Ann CardioThorac Surg 2023;12:492-99.

Pre-emptive Segmental Artery Embolization

ColumbiaDoctors Aortic Center | NewYork-Presbyterian

Haunschmid, et al. Ann CardioThorac Surg 2023;12:492-99.

Sac Rx – foam plugs

- Soft and Conformable Shape Memory Polymer
- FDA approved for vascular embolization - 2018

ColumbiaDoctors Aortic Center | NewYork-Presbyterian

Sac Mgmt. with Shape Memory Polymer

Goal: Manage the Sac

- Stable clot formation
- Reduce T2 EL
- Prevent sac growth
- Aneurysm regression

ColumbiaDoctors Aortic Center | NewYork-Presbyterian

First Clinical Experience

• FIH experience, prophylactic AAA sac management

- 18 patients, 2 German centers, 2019-2021
- IMPEDE-FX, IMPEDE-FX RapidFill
- 100% technical success
- **Sac regression in all patients with ≥3m follow-up (mean 11m)**
- Sac regression even in presence of small T2 endoleaks
- No morbidity or mortality related to treatment

Conclusion: Sac management with Shape Memory Polymer appears feasible and safe in small case series

ColumbiaDoctors Aortic Center | NewYork-Presbyterian

Macrae A. European Radiology Experimental. 2024;3:32.

AAA-SHAPE Early Feasibility Study

• Prospective, multicenter safety trial

- 35 patients
- **100% technical success**
 - Endurant II/III (51%), Excluder/Conformable (49%)
 - Mean IMPEDE-FX RapidFill devices 12 (5-27)
- **No device- or procedure-related MAEs**
- **Four reinterventions related to EVAR procedure for:**
 - Type 1a endoleak
 - EVAR limb stenosis
 - EVAR limb occlusion
 - Partial coverage of left renal artery with EVAR graft

AAA-SHAPE NZ
Andrew Holden, Andrew Hill
Auckland City Hospital, Auckland
Manar Khashram
Waikato District Health Board, Hamilton

AAA-SHAPE NLD
Michel Roijen
Rijnstate Hospital, Arnhem
Jan Heyligers
St. Elisabeth Hospital, Tilburg
Arno Wiersema
Dijklander Hospital, Hoorn

ColumbiaDoctors Aortic Center | NewYork-Presbyterian





